FDA Panel Narrowly Supports BioMimetic's Augment Synthetic Bone Graft
This article was originally published in The Gray Sheet
FDA's Orthopedic and Rehabilitation Devices advisory panel narrowly supported approval of BioMimetic Therapeutics’ Augment synthetic bone graft May 12.
You may also be interested in...
Firm expects to gain PMA approval in 2013 for BioMimetic’s Augment bone graft as a replacement for autologous bone graft in foot and ankle fusion procedures. Deal includes $190 million down, and up to $190 million more in milestone payments.
BioMimetic Therapeutics submits PMA amendment for its Augment bone graft device to address questions raised by FDA in a “not approvable” letter disclosed in January.
Boston Scientific’s TruePath for chronic total occlusions in the peripheral vasculature, Medtronic’s DF4 ICD/CRT-D lead connector, and Toshiba’s Aquilion Prime computed tomography system are among new products on the market.